Destiny Pharma announces positive update from US FDA on XF-73 Phase 3 development plans
- FDA clarifies Phase 3 and US registration pathway for XF-73 Nasal gel for the prevention of post-surgical staphylococcal infections
- Feedback enables the Phase 3 study design to be simplified and is expected to shorten the overall clinical development timelines
Brighton, United Kingdom – 19th July 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, is pleased to announce that it has received positive feedback from the US Food and Drug Administration (FDA) on the proposed XF-73 Nasal US Phase 3 study design and development programme.
